Journal updates

UK lipid guidance recommends Lp(a) measurement in enhanced lipid profiling

January 22, 2025

New UK lipid guidance recommends Lp(a) measurement to be included in enhanced lipid profiling for patients with a personal or family history of premature atherosclerotic cardiovascular disease (ASCVD), first-degree relatives with raised serum Lp(a), familial hypercholesterolemia (FH) or other genetic dyslipidaemias, calcific aortic valve stenosis, or a moderate (10-15%) 10-year risk of a cardiovascular event.

Apo(a) isoform size affects Lp(a) response to lipid lowering therapy 

January 15, 2025

People with larger apo(a) size have the greatest reduction in Lp(a) level in response to potent lipid lowering therapy (LLT). This was one of the findings from the Phase 4 CHOlesterol Reduction and Residual Risk in Diabetes (CHORD) study in which participants with LDL-C >100 mg/dL with and without diabetes (DM) received LLT for 30 […]

Elevated Lp(a) linked to MACE independently of hs-CRP level 

January 6, 2025

Elevated Lp(a) is associated with an increased risk of major adverse cardiovascular events (MACE) independently of hs-CRP level in both primary and secondary prevention populations. This is the conclusion from a systematic review and meta analysis of data from 11 studies, involving 562,301 participants, that reported the relationship between Lp(a) and MACE, stratified by hs-CRP […]

Zerlasiran and muvalaplin studies published 

December 31, 2024

Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) have been published.

Lowering LDL-C does not fully offset ASCVD risk of elevated Lp(a) 

December 18, 2024

Lp(a) and LDL-C have independent and additive adverse effects on risk of atherosclerotic cardiovascular disease (ASCVD), and lowering LDL-C does not fully offset Lp(a)-mediated risk, according to the results of a meta-analysis of data from 27,658 participants enrolled in six placebo-controlled statin trials (4D, 4S, CARDS, JUPITER, LIPID, MIRACL). The studies assessed the association of […]

More evidence of intraindividual Lp(a) variability

December 11, 2024

Analysis of placebo-treated patients in the Phase 2 OCEAN(a)-DOSE trial of olpasiran in patients with Lp(a) concentration >150 nmol/L and established atherosclerotic cardiovascular disease (ASCVD) has shown notable intraindividual variability in serial Lp(a) concentration during follow-up.